Staurosporine (GMP)

Staurosporine (AM-2282) (GMP) is Staurosporine (HY-15141) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases[1][2][3][4][5].

Product Specifications

CAS Number

[62996-74-1]

Product Name Alternative

Antibiotic AM-2282 (GMP) ; STS (GMP) ; AM-2282 (GMP)

UNSPSC

12352005

Hazard Statement

H361, H413

Target

PKC

Type

GMP Small Molecules

Related Pathways

Epigenetics; TGF-beta/Smad

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/staurosporine-gmp.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83

Molecular Formula

C28H26N4O3

Molecular Weight

466.53

Precautions

H361, H413

References & Citations

[1]Ganapathy PS, et al. Sensitivity of staurosporine-induced differentiated RGC-5 cells to homocysteine. Curr Eye Res. 2010 Jan;35 (1) :80-90.|[2]Pregi N, et al. Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells. Biochim Biophys Acta. 2006 Feb;1763 (2) :238-46.|[3]Hajimu MORIOKA, et al. Staurosporine-induced Differentiation in a Human Neuroblastoma Cell Line, NB-1. Agricultural and Biological Chemistry. 1985; 1959-1963.|[4]Okazaki T, et al. Staurosporine, a novel protein kinase inhibitor, enhances HL-60-cell differentiation induced by various compounds. Exp Hematol. 1988 Jan;16 (1) :42-8. |[5]Yuste VJ, et al. The prevention of the staurosporine-induced apoptosis by Bcl-X (L), but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells. J Neurochem. 2002 Jan;80 (1) :126-39.